the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement

Recruitment & Eligibility

Inclusion Criteria

Adult men and women over 19 and under 75 years
After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice

Exclusion Criteria

If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕
Those who received influenza vaccination within 2 months before first intake of intervention
Those who have a body mass index(BMI) of less than 18.5 kg / m^2 or greater than 35 kg / m^2 at the screening
Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic and gastrointestinal disorders
Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening
Those who have received antipsychotic medication within 3 months before screening
Those who alcoholic or drug abuse suspected
Those who participated in other clinical trials within 3 months before screening
Laboratory test by show the following results
- Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit
- Serum Creatinine > 2.0 mg/dL
Pregnancy or breast feeding
Those who doesn't accept the implementation of appropriate contraception of a childbearing woman
Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Study & Design

Arm && Interventions

Group	Intervention	Description
Curcuma longa L. extract mixture group	Curcuma Longa Extract Mixture	2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 1 g/day)
placebo group	placebo group	2 times a day, 2 capsule for 1 time, after breakfast and dinner meal (1.6 g/day, Curcuma longa L. extract mixture 0 g/day)

Primary Outcome Measures

Name	Time	Method
Changes of Natural Killer cell activity	baseline and 8 weeks	Natural Killer cell activity was measured in study baseline and 8 week, using A ratio of effector cell to target cell ratio of 2.5:1, 5:1, 10:1. Natural Killer cell activity(%) = (Experimental - Effector Spontaneous - Target Spontaneous) / (Target Maximum - Target Spontaneous) × 100

Secondary Outcome Measures

Name	Time	Method
Changes of Interleukin-2, Interleukin-12, Interferon-Gamma and Tumor necrosis factor-alpha	baseline and 8 weeks	For blood Interleukin-2(pg/mL), Interleukin-12(pg/mL), Interferon-Gamma(pg/mL) and Tumor necrosis factor-alpha(pg/mL) analysis, collect 3 ml of blood in one serum separate tube for 5 ml, leave at room temperature for 30 minutes for clotting, after then centrifuge at 3000 rpm (or 2000 xg) for 10 minutes.
Changes of Wisconsin Upper Respiratory Symptom Survey-21(WURSS-21)	baseline, 4 weeks and 8 weeks	The Wisconsin Upper Respiratory Symptom Survey-21 will investigate on the day of visit (1st, 2nd and 3rd visits). The Wisconsin Upper Respiratory Symptom Survey-21 consists of seven stages, including individual symptoms, functional quality of life, and overall improvement. Find the total score of symptoms by obtaining the sum of symptom questions, and the total score of quality of life by obtaining the sum of life questions. Additionally, the sum of the total points of symptoms and quality of life is obtained. * All items of symptom score rank on a seven-point scale(1=very mild and 7=severe), where a higher score means higher severity. The symptom score ranges from 0(Do not have this symptom) to 70. * All items of quality of life score rank on a seven-point scale(1=very mildly and 7=severely), where a higher score means higher severity. The quality of life score ranges from 0(Not at all) to 63. * Therefore, the total score ranges from 0 to 133.

Recruitment & Eligibility